Nicole DeBlase

Vicente described Americas pricing as stable at 1% to 2% with no dramatic changes; Vik guided PST second-half margins toward 32% or slightly better.

Vicente highlighted PST 2-year stack organic orders in mid-single digits, consistent with target algorithm. Life Sciences and short-cycle momentum continuing into April.

Vicente confirmed progressive improvement through Q1 and into April. Vik provided enterprise mix: 40% aftermarket, 75% of remaining equipment is shorter cycle, 25% longer-cycle projects. Split relatively equitable between segments.

Vicente noted resurgence of funnel additions at end of 2025 and good start into 2026. Decision-making elongation persists but no cancellations. Funnel continues to grow, boding well for 2026 orders.

Vik confirmed comparable trajectory between segments with PST slightly healthier. Both follow similar sequential improvement pattern from Q1 into back half.

Vik confirmed approximately 1-year payback on headcount actions across the globe. Decent proxy for 2026 benefit sizing.

Vicente confirmed willingness to do more buybacks alongside M&A if continued share price dislocation. Balance sheet supports both strategies simultaneously.

Vik declined to guide on orders specifically. Referenced July MQL momentum and Q2 exit trends as comparable. Noted tariff uncertainty still in wake but more certainty could drive acceleration.

Vicente noted material handling continues to do well within the segment. New Power Tool product launches going into market. Business margins near fleet average and generates good cash. Q1 orders had been positive.

Vicente noted mid-single-digit organic order growth in ITS within Europe, better than expected stability assumption.

Vik confirmed minimal tariff impact on Q1 margins. Carryover pricing from prior year provided some buffer. Tariff cost/price dynamic begins in Q2.

Vik sized China procurement at single-digit % of COGS, described tiered mitigation plans and referenced successful 2021 tariff navigation. Canada/Mexico impact small.

Vicente described legacy medical as stable, not accelerating. FY2025 guidance assumes no V-shaped recovery, keeping expectations muted.

Anurag held stranded costs at $150M and investments at $225M for the year, with productivity running better than expected.

Anurag said 3M bought $3B of stock at ~$153 average in the first half and will stay opportunistic and disciplined.

Maheshwari said $0.05 upside from productivity (mostly realized in Q1) and $0.05 from capital deployment (share buybacks). Brown confirmed no changes to productivity, stranded cost, or tariff assumptions.

Bill confirmed China decelerating from mid-single digits in 2025 to low-to-mid single digits in 2026 with IPI down ~2pts per forecasts.

Bill quantified potential new Europe tariff impact at $30-40M this year if enacted, not yet in guidance; MMM is net exporter to Europe.

Bill cited US up nearly 4%, Europe +2pts (vs -1pt in H1), China up 8% in Q3 driven by local team execution and org changes.

Bill confirmed electronics up mid-single digits, ~10% of sales, with good mainstream penetration in notebooks, tablets, PCs, cell phones.

Bill said Q2 orders up low single digits, backlog grew 1% sequentially to $2B, 20-25% H2 coverage; consumer accelerated through quarter; July similar, no significant prebuy pattern.

Bill flagged auto as Europe watch item with IHS builds down; SIBG Europe up in quarter with some growth signs; Europe flat overall in Q2.

Anurag confirmed $225M growth investment track with $50M in Q1 and big Q2 step-up; R&D 4.8% of sales (vs 4.2% LY); Q1 G&A structural ~$50M improvement, $0.10 hedge taken for guidance.

Bill cited global auto builds -1.8%, US -9%, Europe -4-5%, China up modestly; 1.5M units removed from forecast; auto OE down mid-single for year; consumer electronics flat to low single digits.

Bill said China-for-China grew ~3% in 2024, export half driven by electronics; watching tariff impact on export; December/January activity could include pre-buy; 2025 outlook low-single digit growth.

Bill said actively engaged in arbitration and litigation with insurance carriers for PFAS and Combat Arms; Q4 recovery $170M bringing 2024 total to $340M; expects insurers to honor policy commitments.

Paulo characterized the back-half guide as prudent after a 450bps raise, with no pull-forward and continued upside bias.

Paulo confirmed 12 of 24 facility expansions complete, 6 more by year-end, 6 beyond 2027. Would not expect another investment of this magnitude. Focus on sweating assets and continuous improvement rather than another large tranche.

Paulo highlighted utility orders up low teens in EA and mid-single digits in EG on LTM basis. Aerospace accelerated to 12% full-year growth with 90bps margin expansion. Short-cycle showing green shoots in global, expected to inflect positively in Americas including residential, but maintaining cautious guidance stance.

Paulo confirmed Q4 2025 and Q1 2026 absorbed the heaviest ramp-up costs, with sequential improvement expected through the year. The margin cadence reflects hiring and depreciation costs ahead of revenue ramp from new capacity.

Olivier cited prudence with H2 restructuring costs, while noting long-term goal of closing the margin gap with EA through portfolio actions and simplification.

Paulo highlighted data center order traction in Europe, short-cycle green shoots, continued double-digit APAC growth, and openness to inorganic actions.

Paulo stated end market outlook unchanged at ~7% with a little more pricing from tariffs and a little more volume, with organic growth raise driven by backlog confidence.

Olivier broke down the $0.10 shift: $0.06 corporate (Fiber Bond interest + executive comp timing) and $0.04 Q2 tariff timing delay on pricing recovery.

Paulo confirmed bolt-on acquisitions in Electrical and Aerospace as focus, with strong cash position leaving room for strategic M&A.

Paulo attributed moderate margin expansion to startup costs from two dozen capacity projects and shift from pricing to volume-driven growth.

Vimal agreed the seven-quarter high-single-digit streak has no logic to break given the high-growth-vertical pivot, but flagged prudence in the guide as a newly standalone company.

Mike said stranded costs are tracking about $20 million better than the Investor Day plan, with roughly $60 million to $65 million expected to enter 2027 for early elimination.

Vimal broke down orders: IA up 10%, BA up 9%, PA&T up 3%, Aero up 6%. Short-cycle demand is favorable with BA continuing strong and IA China/Europe recovering.

Jim confirmed all 3 subsegments were impacted as the same mechanical supply base serves commercial OE, aftermarket and defense. Q2 improvement expected to be broad-based.

Short-cycle orders bifurcated by geography: US, META, India strong; Europe and China soft especially in IA. Q1 2026 expects high single-digit overall orders with mid-single-digit short cycle in BA and Aero.

IA expected to lead all segments with ~100 bps margin expansion in 2026. Driven by productivity actions, pricing leverage, and fixed-cost reduction. Largest operational improvement opportunity across the portfolio.

Short-cycle trends improved in Q3. Similar dynamics expected in Q4 with no substantial change quarter-over-quarter. CEO remains prudent in guidance on near-term macro unknowns.

Aero led Q2 order growth at 6%. June softness in IA and ESS appears to be a false positive as July orders continuing strong. No concern about order rates slowing.

Pipeline remains strong but pace moderating given spins in motion. Carve-out deal capability demonstrated repeatedly, expanding optionality. Portfolio optimization remains high priority.

CEO said the Middle East is about 10% of EMEA and remains challenging with no expected near-term change; CFO guided EMEA to very low single digit to flat in Q4.

Marc said APAC Q2 had strong 13% growth and ~$20M productivity uplift. Q3-Q4 growth closer to mid-single-digit so margins flat YoY in Q3, but full-year margin expected in high 18% range.

Marc confirmed it's not a crazy assumption for a step-up in FY2027 H1 but noted potential headwinds from service business and less differentiated portfolio segments that could moderate growth.

Data center, biologics manufacturing, university/hospital research campuses, and semicon/advanced manufacturing driving outsized backlog growth. $15B record backlog.

First-half growth lower due to tough comps, second-half acceleration. Record backlog and recurring service provide strong visibility. Compares issue, not demand.

Two factors: tariff uncertainty leading to conservatism, and the business becoming longer-cycle post-Resi divestiture, reducing seasonal variation.

Some macro uncertainty built into guide for ~25% shorter-cycle portion. Long-cycle backlog and recurring service provide strong visibility for the majority.

Marc expects backlog to keep growing given the pipeline, underpinning confidence in mid-single-digit revenue growth for fiscal 2025.

Michael confirmed a small second-half absorption headwind tied to holding inventory reduction targets on lower sales volumes.

Michael pointed to continued BCS volume growth at 35% incrementals with price-cost neutral, and Alok said all three BCS businesses are performing well.

CFO said Q2 absorption headwind will be between zero and $15M, fully behind them by end of Q2. CEO added that $15M makes a big difference when Q1 profit is only ~$160M but is immaterial in the more profitable Q2.

CEO confirmed the overall commercial unitary market still declined in Q1 but rate of decline is improving. Lennox clearly outperforming through full life cycle offerings, emergency replacement, and services. Market share remains very small with significant runway.

CEO confirmed competitors targeting similar pricing. Some low-end RNC business getting more competitive but Lennox choosing to walk away from that. Broad-based industry pricing discipline remains intact across the US.

CFO acknowledged Q1 EPS will be more pronounced to the downside from absorption. Cost productivity accelerates in Q2 to mitigate. Revenue drives margins at 35% decremental/incremental with productivity and absorption as modifiers.

CEO confirmed the emergency replacement sales force investment is complete with no incremental spend. YoY comparisons will lap by second half 2025.

CFO said new construction is 20% of HCS and expected to be flattish, with pent-up demand contingent on interest rate declines. Overall margins guided flat: up in BCS, down in HCS.